These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25642595)

  • 41. Further demonstration of kappa opioid binding sites in the brain: evidence for heterogeneity.
    Su TP
    J Pharmacol Exp Ther; 1985 Jan; 232(1):144-8. PubMed ID: 2856939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identifying multiple active conformations in the G protein-coupled receptor activation landscape using computational methods.
    Dong SS; Goddard WA; Abrol R
    Methods Cell Biol; 2017; 142():173-186. PubMed ID: 28964335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of Ligand Binding to GPCRs Through Computational Methods.
    Vasile S; Esguerra M; Jespers W; Oliveira A; Sallander J; Åqvist J; Gutiérrez-de-Terán H
    Methods Mol Biol; 2018; 1705():23-44. PubMed ID: 29188557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes.
    Leonis G; Avramopoulos A; Salmas RE; Durdagi S; Yurtsever M; Papadopoulos MG
    J Chem Inf Model; 2014 Aug; 54(8):2294-308. PubMed ID: 25060329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation.
    Kim SK; Goddard WA; Yi KY; Lee BH; Lim CJ; Trzaskowski B
    ChemMedChem; 2014 Aug; 9(8):1732-43. PubMed ID: 24989481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.
    Dogra S; Yadav PN
    Eur J Pharmacol; 2015 Sep; 763(Pt B):184-90. PubMed ID: 26164787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nanobody-enabled monitoring of kappa opioid receptor states.
    Che T; English J; Krumm BE; Kim K; Pardon E; Olsen RHJ; Wang S; Zhang S; Diberto JF; Sciaky N; Carroll FI; Steyaert J; Wacker D; Roth BL
    Nat Commun; 2020 Mar; 11(1):1145. PubMed ID: 32123179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.
    Che T; Majumdar S; Zaidi SA; Ondachi P; McCorvy JD; Wang S; Mosier PD; Uprety R; Vardy E; Krumm BE; Han GW; Lee MY; Pardon E; Steyaert J; Huang XP; Strachan RT; Tribo AR; Pasternak GW; Carroll FI; Stevens RC; Cherezov V; Katritch V; Wacker D; Roth BL
    Cell; 2018 Jan; 172(1-2):55-67.e15. PubMed ID: 29307491
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kappa-opioid receptor model in a phospholipid bilayer: molecular dynamics simulation.
    Iadanza M; Höltje M; Ronsisvalle G; Höltje HD
    J Med Chem; 2002 Oct; 45(22):4838-46. PubMed ID: 12383009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GPCR-G protein selectivity revealed by structural pharmacology.
    Bernhard SM; Han J; Che T
    FEBS J; 2024 Jul; 291(13):2784-2791. PubMed ID: 38151714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Ligand recognition in the opioid receptors by modeling methods and the design of opioids].
    Kanematsu K
    Yakugaku Zasshi; 1998 Jan; 118(1):1-18. PubMed ID: 9484038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicted 3D structures of olfactory receptors with details of odorant binding to OR1G1.
    Kim SK; Goddard WA
    J Comput Aided Mol Des; 2014 Dec; 28(12):1175-90. PubMed ID: 25224127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural determinants of diphenethylamines for interaction with the κ opioid receptor: Synthesis, pharmacology and molecular modeling studies.
    Guerrieri E; Bermudez M; Wolber G; Berzetei-Gurske IP; Schmidhammer H; Spetea M
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4769-4774. PubMed ID: 27567368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist.
    Mafi A; Kim SK; Goddard WA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5836-5843. PubMed ID: 32127473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Galpha-subunits differentially alter the conformation and agonist affinity of kappa-opioid receptors.
    Yan F; Mosier PD; Westkaemper RB; Roth BL
    Biochemistry; 2008 Feb; 47(6):1567-78. PubMed ID: 18205395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-chain fluorescent integrators for mapping G-protein-coupled receptor agonists.
    Kroning K; Gannot N; Li X; Putansu A; Zhou G; Sescil J; Shen J; Wilson A; Fiel H; Li P; Wang W
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2307090121. PubMed ID: 38648487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of action of the diazabicyclononanone-type kappa-agonists.
    Holzgrabe U; Brandt W
    J Med Chem; 2003 Apr; 46(8):1383-9. PubMed ID: 12672238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In silico design of novel probes for the atypical opioid receptor MRGPRX2.
    Lansu K; Karpiak J; Liu J; Huang XP; McCorvy JD; Kroeze WK; Che T; Nagase H; Carroll FI; Jin J; Shoichet BK; Roth BL
    Nat Chem Biol; 2017 May; 13(5):529-536. PubMed ID: 28288109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists.
    Goddard WA; Abrol R
    J Nutr; 2007 Jun; 137(6 Suppl 1):1528S-1538S; discussion 1548S. PubMed ID: 17513420
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods.
    Cheng J; Liu G; Zhang J; Xu Z; Tang Y
    J Mol Model; 2011 Mar; 17(3):477-93. PubMed ID: 20499259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.